136 related articles for article (PubMed ID: 17118317)
1. A descriptive analysis of postimplant dosimetric parameters from Radiation Therapy Oncology Group P0019.
Lee WR; Bae K; Lawton CA; Gillin MT; Morton G; Firat S; Baikadi M; Kuettel M; Greven K; Sandler H
Brachytherapy; 2006; 5(4):239-43. PubMed ID: 17118317
[TBL] [Abstract][Full Text] [Related]
2. Dose-volume conundrum for response of prostate cancer to brachytherapy: summary dosimetric measures and their relationship to tumor control probability.
D'Souza WD; Thames HD; Kuban DA
Int J Radiat Oncol Biol Phys; 2004 Apr; 58(5):1540-8. PubMed ID: 15050335
[TBL] [Abstract][Full Text] [Related]
3. Is there a role for postimplant dosimetry after real-time dynamic permanent prostate brachytherapy?
Potters L; Calugaru E; Jassal A; Presser J
Int J Radiat Oncol Biol Phys; 2006 Jul; 65(4):1014-9. PubMed ID: 16682144
[TBL] [Abstract][Full Text] [Related]
4. Dosimetric quality endpoints for low-dose-rate prostate brachytherapy using biological effective dose (BED) vs. conventional dose.
Singh R; Al-Hallaq H; Pelizzari CA; Zagaja GP; Chen A; Jani AB
Med Dosim; 2003; 28(4):255-9. PubMed ID: 14684190
[TBL] [Abstract][Full Text] [Related]
5. Effect of prostate size and isotope selection on dosimetric quality following permanent seed implantation.
Merrick GS; Butler WM; Dorsey AT; Lief JH
Tech Urol; 2001 Sep; 7(3):233-40. PubMed ID: 11575521
[TBL] [Abstract][Full Text] [Related]
6. Dosimetry and cancer control after low-dose-rate prostate brachytherapy.
Robert Lee W; Deguzman AF; McMullen KP; McCullough DL
Int J Radiat Oncol Biol Phys; 2005 Jan; 61(1):52-9. PubMed ID: 15629593
[TBL] [Abstract][Full Text] [Related]
7. Rectal function following brachytherapy with or without supplemental external beam radiation: results of two prospective randomized trials.
Merrick GS; Butler WM; Wallner KE; Galbreath RW; Kurko B; Cleavinger S
Brachytherapy; 2003; 2(3):147-57. PubMed ID: 15062137
[TBL] [Abstract][Full Text] [Related]
8. Prostate brachytherapy post-implant dosimetry: a comparison between higher and lower source density.
Thomas CW; Kruk A; McGahan CE; Spadinger I; Morris WJ
Radiother Oncol; 2007 Apr; 83(1):18-24. PubMed ID: 17368844
[TBL] [Abstract][Full Text] [Related]
9. Factors predictive of rectal bleeding after 103Pd and supplemental beam radiation for prostate cancer.
Sherertz T; Wallner K; Merrick G; Ford E; Sutlief S; Cavanagh W; Butler W; True L
Brachytherapy; 2004; 3(3):130-5. PubMed ID: 15533804
[TBL] [Abstract][Full Text] [Related]
10. Comparative study of permanent interstitial prostate brachytherapy post-implant evaluation among seven Italian institutes.
Mangili P; Stea L; Cattani F; Lappi S; Giglioli F; Calamia E; Ziglio F; Martinelli R; Longobardi B
Radiother Oncol; 2004 Apr; 71(1):13-21. PubMed ID: 15066291
[TBL] [Abstract][Full Text] [Related]
11. Toward a dynamic real-time intraoperative permanent prostate brachytherapy methodology.
Potters L; Calguaru E; Thornton KB; Jackson T; Huang D
Brachytherapy; 2003; 2(3):172-80. PubMed ID: 15062140
[TBL] [Abstract][Full Text] [Related]
12. High-dose regions versus likelihood of cure after prostate brachytherapy.
Wallner K; Merrick G; Sutlief S; True L; Butler W
Int J Radiat Oncol Biol Phys; 2005 May; 62(1):170-4. PubMed ID: 15850918
[TBL] [Abstract][Full Text] [Related]
13. Correlation between real-time intraoperative and postoperative dosimetry and its implications on intraoperative planning.
Yan C; Huq MS; Heron DE; Beriwal S; Wynn RB
Brachytherapy; 2019; 18(3):338-347. PubMed ID: 30655047
[TBL] [Abstract][Full Text] [Related]
14. Update on brachytherapy in localized prostate cancer: the importance of dosimetry.
Urbanic JJ; Lee WR
Curr Opin Urol; 2006 May; 16(3):157-61. PubMed ID: 16679852
[TBL] [Abstract][Full Text] [Related]
15. CT-ultrasound fusion prostate brachytherapy: a dynamic dosimetry feedback and improvement method. A report of 54 consecutive cases.
Fuller DB; Jin H; Koziol JA; Feng AC
Brachytherapy; 2005; 4(3):207-16. PubMed ID: 16182221
[TBL] [Abstract][Full Text] [Related]
16. Dosimetric parameters as predictive factors for biochemical control in patients with higher risk prostate cancer treated with Pd-103 and supplemental beam radiation.
Orio P; Wallner K; Merrick G; Herstein A; Mitsuyama P; Thornton K; Butler W; Sutlief S
Int J Radiat Oncol Biol Phys; 2007 Feb; 67(2):342-6. PubMed ID: 17236959
[TBL] [Abstract][Full Text] [Related]
17. Prostate brachytherapy postimplant dosimetry: seed orientation and the impact of dosimetric anisotropy in stranded implants.
Chng N; Spadinger I; Rasoda R; Morris WJ; Salcudean S
Med Phys; 2012 Feb; 39(2):721-31. PubMed ID: 22320782
[TBL] [Abstract][Full Text] [Related]
18. The correlation between D90 and outcome for I-125 seed implant monotherapy for localised prostate cancer.
Ash D; Al-Qaisieh B; Bottomley D; Carey B; Joseph J
Radiother Oncol; 2006 May; 79(2):185-9. PubMed ID: 16701911
[TBL] [Abstract][Full Text] [Related]
19. Intraoperative real-time planned conformal prostate brachytherapy: post-implantation dosimetric outcome and clinical implications.
Zelefsky MJ; Yamada Y; Cohen GN; Sharma N; Shippy AM; Fridman D; Zaider M
Radiother Oncol; 2007 Aug; 84(2):185-9. PubMed ID: 17692978
[TBL] [Abstract][Full Text] [Related]
20. Technical acquisition and dosimetric assessment of iodine-125 permanent brachytherapy in localized prostate cancer: our first series of 100 patients.
Tanaka N; Asakawa I; Kondo H; Tanaka M; Fujimoto K; Hasegawa M; Konishi N; Hirao Y
Int J Urol; 2009 Jan; 16(1):70-4. PubMed ID: 19120529
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
